UPDATE -- New England Journal of Medicine Publishes Pivotal

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease

CRANBURY, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the August 11 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here  and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com .

"We are very pleased and honored that the New England Journal of Medicine has published our pivotal Phase 3 FACETS study in treatment-naïve Fabry patients,” said Jay Barth, MD, Chief Medical Officer of Amicus Therapeutics, Inc. “We believe that this study generated a robust data set and validated our precision medicine approach to identify patients with amenable mutations. This Phase 3 study, together with our Phase 3 ERT-switch Study 012, supported the European Commission’s recent full approval for migalastat in the European Union as a first line therapy for Fabry disease in patients 16 years and older who have an amenable genetic mutation. This publication is a significant milestone, and I would like to express my sincerest gratitude to the physicians who were investigators in this study, as well as to the patients and families who participated in the study.”

Prof. Dominique P. Germain, MD, PhD, Division of Medical Genetics at the University of Versailles (Paris-Saclay University) and Assistance Publique - Hôpitaux de Paris stated, “As a treating physician of Fabry disease patients for 15 years, I believe that significant unmet needs remain for these patients. Migalastat is a paradigm of precision medicine with a unique mechanism of action that was developed through a significant patient-centered research effort to first understand the genetics and mutations of the GLA gene underlying this disease and then to identify more than 250 mutations that are amenable to this chaperone therapy. As the lead author of the journal publication along with 40 colleagues from 12 different countries as co-authors, and having served as principal investigator in France for the migalastat clinical studies for the past decade, I believe that migalastat may offer a differentiated and important personalized treatment option for patients with Fabry disease who have an amenable mutation.”

Migalastat is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of alpha-Gal A, the genotypes of which are referred to as amenable mutations (or “suitable” mutations in the NEJM article). As previously announced , the European Commission has granted full approval for migalastat, under the trade name Galafold™, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Amicus is supplying the market in Germany and has commenced the reimbursement processes with healthcare authorities in each of the major European countries.

About FACETS (Study 011) Study 011 was a Phase 3 study designed to measure the reduction of disease substrate (globotriaosylceramide, or GL-3) following treatment with migalastat in Fabry patients with amenable mutations. The study also measured clinical outcomes, including renal function and left ventricular mass index (LVMi), as secondary endpoints. The 24-month study began with a 6-month double-blind, placebo-controlled treatment period, after which all patients were treated with migalastat for a 6-month open-label follow-up period and a subsequent 12-month open-label extension phase. Fabry patients enrolled in Study 011 were naïve to treatment or had not received enzyme replacement therapy (ERT) for at least 6 months prior to study entry. Upon completion, patients were eligible to roll over into a separate extension to continue migalastat.

About Galafol d™ and Amenable Mutations Galafold™ (migalastat) is a first-in-class chaperone therapy approved in the EU as a monotherapy for Fabry disease in patients with amenable mutations. Galafold works by stabilizing the body’s own dysfunctional enzyme, so it can clear the accumulation of disease substrate in patients who have amenable mutations.  A proprietary in vitro assay (Galafold Amenability Assay) was used to classify more than 800 known GLA mutations as “amenable” or “not amenable” to treatment with Galafold. The current label includes all 269 GLA mutations that have been identified and determined to be amenable based on the Galafold Amenability Assay, which represent between 35% and 50% of the currently diagnosed Fabry population.

Healthcare providers in the EU may access the website www.galafoldamenabilitytable.com to quickly and accurately identify which mutations are categorized as “amenable” or “not amenable” to Galafold. Amicus expects to submit updates to the label as additional GLA mutations are identified and tested in the Galafold Amenability Assay.

Important Safety Information Treatment with GALAFOLD should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. GALAFOLD is not recommended for use in patients with a nonamenable mutation.

  • GALAFOLD is not intended for concomitant use with enzyme replacement therapy.
  • GALAFOLD is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m 2 ). The safety and efficacy of GALAFOLD in children 0–15 years of age have not yet been established.
  • No dosage adjustments are required in patients with hepatic impairment or in the elderly population.
  • There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
  • While taking GALAFOLD, effective birth control should be used. It is not known whether GALAFOLD is excreted in human milk.
  • Contraindications to GALAFOLD include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.
  • It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on GALAFOLD or switched to GALAFOLD.
  • OVERDOSE: General medical care is recommended in the case of GALAFOLD overdose.
  • The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received GALAFOLD. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.
  • Call your doctor for medical advice about side effects.    

For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu .

About Fabry Disease Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A), which are the result of mutations in the GLA gene. The primary biological function of alpha-Gal A is to degrade specific lipids in lysosomes, including globotriaosylceramide (referred to here as GL-3 and also known as Gb 3 ). Lipids that can be degraded by the action of alpha-Gal A are called "substrates" of the enzyme. Reduced or absent levels of alpha-Gal A activity lead to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. Progressive accumulation of GL-3 is believed to lead to the morbidity and mortality of Fabry disease, including pain, kidney failure, heart disease, and stroke. The symptoms can be severe, differ from patient to patient, and begin at an early age. All Fabry disease is progressive and may lead to organ damage regardless of the time of symptom onset.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD ) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

FOLD–G

CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations spellegrino@amicusrx.com (609) 662-5044 Media: MWW PR Sean Conley sconley@mww.com (646) 381-9096

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Madison Achieves Top Rank for Employment Opportunities

Updated Category News Views 256

Madison Tops Functional Employment Rankings Recently, Madison has been recognized as the leading metro area in the country for functional employment, a title derived from a comprehensive analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP). This achievement highlights Madison’s robust job growth, higher wage levels, and an overall favorable work...

Continue Reading
Investors Alert: Class Actions Against WEBTOON, Elanco, and Domino's

Updated Category News Views 131

Class Action Lawsuits Overview In recent developments, Bragar Eagel & Squire, P.C., a well-known shareholder rights law firm, has informed investors about multiple class action lawsuits filed against notable companies such as WEBTOON Entertainment, Inc. (NASDAQ: WBTN), Elanco Animal Health Incorporated (NYSE: ELAN), and Domino's Pizza, Inc. (NYSE: DPZ). Shareholders in...

Continue Reading
Navigating the New Multipolar Reality: Insights for Investors

Updated Category News Views 257

The Shift to a Multipolar World: What Investors Need to Know The global landscape has transformed, moving away from a system dominated by one major power to a multipolar world. This significant shift means that traditional geopolitical assumptions guiding investors are no longer reliable. Marko Papic, Chief Strategist at BCA Research, recently underscored this point in a...

Continue Reading
Jim Cramer Discusses Broadcom's Impact on Market Corrections

Updated Category News Views 211

Market Dynamics and Broadcom's Recent Performance As the Nasdaq 100 index faces a notable correction, Broadcom Inc. (NASDAQ: AVGO) has managed to stand out with a remarkable surge of 12.82% during after-hours trading. However, renowned market analyst Jim Cramer expresses skepticism regarding its ability to reverse the overall market decline. Understanding the Market...

Continue Reading
NSFOCUS Achieves 'Stars Companies' Recognition in DDoS Sector

Updated Category News Views 137

NSFOCUS Achieves Notable Recognition in Cybersecurity In a significant development, NSFOCUS has earned recognition as a 'Stars Company' in the DDoS Protection and Mitigation Security sector by the esteemed MarketsandMarkets' 360Quadrants platform. This accolade reflects NSFOCUS's unwavering commitment to innovation and excellence in delivering cutting-edge solutions for...

Continue Reading